Innovaderm Research, a dual-focus CRO, Appoints Jeff Smith as New CEO

[MONTREAL, QC, January 2025]—Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients.

Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles.

Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation. Innovaderm is excited to add therapeutic expertise in rheumatology in addition to our world class dermatology research services, further expanding our capabilities and dedication to advancing medical knowledge and new therapies as a dual-focused CRO. Mr. Smith’s proven track record in organizational expansion and achieving meaningful and impactful results will be invaluable in driving these efforts forward.

“I am truly honored to join Innovaderm as CEO and collaborate with such a dedicated and talented team.  Together, we are poised to work together with our sponsors to drive innovation in clinical research, making meaningful advancements in dermatology and rheumatology that will directly benefit patients and improve their quality of life.” Jeff Smith

Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the CRO’s continuity and stability. His ongoing leadership will continue to guide Innovaderm’s mission to advance clinical research and improve patient outcomes. “I am confident Jeff Smith’s leadership will drive Innovaderm to new heights.” said Dr. Robert Bissonnette.

For more information about our dermatology and rheumatology services please visit:
https://innovaderm.com

Innovaderm Research Inc.

Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.

For more information:

Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

Original Article
www.businesswire.com

FAQ 

Q: Who is the new CEO of Innovaderm? 

A: We are pleased to announce the appointment of Jeff Smith as the new CEO of Innovaderm.  

Q: Is Dr. Bissonnette retiring or stepping away from Innovaderm? What will Dr. Bissonnette new role be? 

A: No, Dr. Bissonnette will fully dedicate himself to his role as Executive Chairman, providing medical and scientific support to the CRO.  

Q: How does this change affect Innovaderm’s operations? 

A: Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the company’s ongoing stability and consistent leadership.  

Q: Is Innovaderm’s intention behind changing the CEO to lead to a merger and acquisition? 

A: No, Innovaderm is committed to never being sold. Instead, a succession path has been established through the Montreal Dermatology Research Institute to ensure the continuity and stability of Innovaderm’s mission beyond Dr. Bissonnette’s tenure, guaranteeing that the organization remains dedicated to its core values and objectives. Importantly, Innovaderm’s decision behind this leadership change is to allow Dr. Bissonnette to fully dedicate himself to his role as Executive Chairman, where he can provide focused medical and scientific support to the organization. This strategic reallocation ensures continuity and stability within Innovaderm, while also enhancing the leadership structure to better serve our clients and drive future growth. 

Q: Will this internal change affect any ongoing studies? 

A: No, this internal change does not affect any ongoing studies.  

Q: Where can I find more information about this announcement? 

A: You can read the full press release here: Link

Newsletter